Table 1 Demographic and clinical characteristics of patients with Hurthle cell carcinoma
Variable | Number | Percent |
|---|---|---|
Gender | ||
Female | 187 | 78.2 |
Males | 52 | 21,8 |
Age | 54,3 ± 13,7 | |
20–29 | 10 | 4,2 |
30–39 | 28 | 11,7 |
40–49 | 46 | 19,2 |
50–59 | 66 | 27,6 |
60–69 | 53 | 22,2 |
> 70 | 36 | 15,1 |
pT tumor stage | ||
T1 | 19 | 7,9 |
T2 | 112 | 46,9 |
T3 | 75 | 31,4 |
T4 | 33 | 13,8 |
N stage | ||
N0 | 72 | 30,1 |
N1a | 5 | 2,1 |
N1b | 1 | 0,4 |
Nx | 161 | 67,4 |
Tumor invasiveness | ||
minimally invasive | 102 | 67,1 |
widely invasive | 50 | 32,9 |
Tumor size (mm) | ||
<39 | 93 | 46 |
≥40 | 109 | 54 |
Capsular invasion | ||
transcapsular | 152 | 69,7 |
no or minimal | 66 | 30,3 |
Vascular invasion | ||
positive | 146 | 67 |
no or minimal | 72 | 33 |
Number of tumor focuses | ||
one focus | 167 | 76,6 |
multicentric | 51 | 21,3 |
Regional tumor infiltration | ||
positive | 33 | 13,8 |
negative | 206 | 86,2 |
Thyroglobulin | ||
normal values (<68 ng/mL) | 19 | 26,8 |
elevated values (>68 ng/mL) | 52 | 73,2 |
Radioiodine ablation after surgery | ||
Yes | 65 | 36,9 |
No | 111 | 63,1 |
Surgeon experience | ||
resident | 11 | 4,6 |
specialist 1–5 years | 20 | 8,4 |
specialist 6–10 years | 57 | 23,8 |
specialist over 10 years | 151 | 63,2 |